|
| |
-
- Health Care
-
-
- How Elected officials vote on health care
and accept money from health care industry lobbies.
There may be no better sign of the changing debate over the nation's farm
subsidies: A Midwestern governor running for president calls for cuts in a
system that has steered hundreds of millions of dollars a year to his state.
Click on Everybody In
Nobody Out... to see a website that supports state organizations
working at the grassroots for universal health care (UHC).
On this website you will see:
Philosophy and History of the
"Right to Health Care".
By history of the "Right to Health
Care" we mean the history of the concept. If you are
looking for the history of this human right being
formally recognized and established throughout the world
and in the United States, then you might prefer starting
in our section "Signed
Documents". |
|
|
"Everybody In Nobody Out" is the website of Project
EINO, which is an organizing effort committed to the support and advancement of
state and local organizations working towards non-incremental universal health
care. Project EINO also works to advance the discussion in states where no
state UHC group presently operate, with the hope that new activist groups might
arise. Interested in starting a new state UHC group?
Click Here.
Contributions from Health Care
Industries to Congress from 1990 to 2006 is found at:
http://www.crp.org/industries/indus.asp?Ind=H04
Total contributions are $134,691,165.
Courtesy of Center for Responsive Politics.
Health Insurance
Coverage
Overview
- The number of people with health
insurance coverage increased by 1.4 million to 247.3 million
between 2004 and 2005, and the number without such coverage rose
by 1.3 million to 46.6 million (from 15.6 percent in 2004 to
15.9 percent in 2005).
- Between 2004 and 2005, people
covered by employment-based health insurance (174.8 million)
declined from 59.8 percent to 59.5 percent.
- While the number of people covered
by government health programs increased between 2004 and 2005,
from 79.4 million to 80.2 million, the percentage of people
covered by government health insurance remained at 27.3 percent.
There was no statistical difference in the number or percentage
of people covered by Medicaid (38.1 million and 13.0 percent,
respectively) between 2004 and 2005.
- The proportion and number of
uninsured children increased between 2004 and 2005, from 10.8
percent to 11.2 percent and from 7.9 million to 8.3 million,
respectively.
http://www.census.gov/Press-Release/www/releases/archives/income_wealth/007419.html
Americans With No Health Insurance Rises
Census figures show that a record 46.6 million
Americans, including 8.3 million children, had no health insurance in 2005, up
from 45.3 million in 2004. Meanwhile, premiums for those with coverage were up
7.7 percent in 2006, to $11,480 for a family of four in employer-sponsored plans
http://www.washingtonpost.com/wp-dyn/content/article/2006/12/24/AR2006122400589.html
Off the Charts: Pay, Profits and Spending by Drug Companies.
Refuting industry claims that high drug prices are
necessary to sustain research and development efforts.
LINKS HIGH DRUG PRICES TO ADVERTISING, PROFITS, AND ENORMOUS
EXECUTIVE SALARIES
Washington, D.C. - A new report by the consumer health
organization Families USA refutes the pharmaceutical industry's claim that high
and increasing drug prices are needed to sustain research and development. The
report documents that drug companies are spending more than twice as much on
marketing, advertising, and administration than they do on research and
development; that drug company profits, which are higher than all other
industries, exceed research and development expenditures; and that drug
companies provide lavish compensation packages for their top executives.
| Company |
.
Revenue
Net Sales in
millions of dollars:
. |
Percent of Revenue Allocated to: |
Profit:
(Net Income) |
Marketing/
Advertising/
Administration |
Research and
Development
(R&D)
|
|
Merck and Co., Inc |
$40,363
_ |
17%
|
15%
|
6%
|
| Pfizer
Inc. |
29,574
|
13%
|
39%
|
15%
|
Bristol-Myers
Squibb Company |
18,216
|
26%
|
30%
|
11%
|
Pharmacia
Corporation |
18,144
|
4%
|
37%
|
15%
|
| Abbott
Laboratories |
13,746
|
20%
|
21%
|
10%
|
American
Home
Products
Corporation |
13,263
|
-18%
|
38% |
13%
|
| Eli
Lilly and Co. |
10,862 |
28% |
30% |
19% |
Schering-Plough
Corporation |
9,815 |
25% |
36% |
14% |
| Allergan, Inc. |
1,563 |
14% |
42%
|
13%
|
Five Highest Paid Drug Company Executives Salaries
2000 Annual Compensation Exclusive of Unexercised Stock Options
Chart 2
| Executive
|
Company
|
Compensation
|
William C. Steere, Jr.
Chairman |
Pfizer
Inc |
$40,191,845
|
John
R. Stafford
Chairman and CEO |
American
Home Products
Corporation |
$27,008,927
|
Edward M. Scolnick
Executive VP |
Merck
and Co., Inc. |
$26,454,600
|
Richard
Jay Kogan
Chairman and CEO |
Schering-Plough
Corporation |
$21,444,020
|
David W. Anstice
President, the Americas |
Merck
and Co., Inc. |
$19,600,975
|
The Five Drug Company Executives Salaries
with the Largest Unexercised Stock Options in 2000
Chart 3
| Executive
|
Company
|
Compensation
|
C.A.
Heimbold, Jr.
Chairman and CEO |
Bristol-Myers
Squibb Company |
$227,869,513
|
Raymond
V. Gilmartin
Chairman, Pres., and CEO |
Merck
and Co., Inc. |
$181,252,976
|
William
C. Steere, Jr.
Chairman |
Pfizer
Inc. |
$130,944,439
|
K.E.
Weg
Vice Chairman |
Bristol-Myers Squibb Company |
$84,282,547
|
John
R. Stafford
Chairman and CEO |
American Home Products
Corporation |
$81,847,569
|
originally posted on
FAMILIES USA
http://www.actupny.org/reports/drugcosts.html#chart_one
|
MAKING THE DRUG
INDUSTRY PLAY FAIR
The following is a statement
released today by Ron Pollack,
executive director of Families USA,
at a forum on Capitol Hill regarding
anticompetitive practices of the
prescription drug industry:
"Numerous lawsuits have been
filed across the country to force
the drug industry to play fair in
the marketplace. These lawsuits -
brought by state attorneys general,
the FTC, consumers, and third-party
payers of health care - are aimed at
stopping anticompetitive practices
that have led to skyrocketing drug
costs.
"Three types of lawsuits are
being litigated and they seek to
vindicate three important
principles. First, do not violate
antitrust and other anticompetitive
laws by preventing more
cost-effective generic drugs from
coming to market. Second, do not
misrepresent information about drug
products by failing to give full or
truthful information to America's
consumers. Third, do not manipulate
drug prices in a manner that results
in huge costs for the Medicare and
Medicaid programs and for the
beneficiaries of those programs.
"Preventing and delaying generic
drugs from coming to market
needlessly increases costs for
consumers including Medicare
beneficiaries as well as third-party
payers of health care. It improperly
extends drug monopolies that enable
the drug companies to profiteer at
the expense of everyone else.
"The lawsuits being litigated are
intended to make the pharmaceutical
marketplace work for everyone. It is
ironic that the drug industry goes
to great lengths to prevent the
regulation of prices in the name of
promoting a free market. But, in
doing so, it undermines competition,
which is the hallmark of a free
market."
For copies of the materials
handed out at the forum please visit
our website
www.familiesusa.org. A webcasts
of this forum will be made available
by kaisernetwork.org, a free service
of the Kaiser Family Foundation,
after 5:00 pm ET on Monday, April
15. The webcasts, transcripts, and
related resources can be found at
http://www.kaisernetwork.org/healthcast/familesusa/15apr02.
http://www.familiesusa.org/resources/newsroom/statements/2002-statements/press-statement-making-the-drug-industry-play-fair.html
|
|
|
|
|
|